The OncLive COVID-19 condition center page is a comprehensive resource for clinical news and expert insights on how the COVID-19 pandemic has impacted multiple areas of oncology care and practice. This page features news articles, interviews in written and video format, and podcasts encompassing data of patients with COVID-19 and cancer, oncology drugs being tested against the virus, vaccine information for patients with cancer, and more.
May 5th 2022
Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendations for fixing peer review, and explaining how this affects cancer research.
April 29th 2022
The National Comprehensive Cancer Network is advising individuals who are immunocompromised, including those with cancer, to receive a fifth COVID-19 vaccination.
April 29th 2022
The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation or cellular therapy following initial failure of seroconversion after the first 2 vaccine doses.
April 27th 2022
Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population
April 12th 2022
CoVac-1, a multi-peptide COVID-19 vaccine, elicited promising T-cell activity and safety in patients with cancer who have disease- or treatment-related immunoglobulin deficiency.
April 7th 2022
Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.
March 27th 2022
Data from a retrospective observational study revealed that White patients with hematologic malignancies in the United States had significantly higher uptake of telemedicine vs Black patients, reflecting disparities that require further exploration.
March 22nd 2022
Muhammad Bilal Abid, MD, MRCP, discusses clinical takeaways regarding the standard use of a third SARS-CoV-2 mRNA vaccine dose among patients treated with hematopoietic cell transplantation, CAR T-cell therapy, and bispecific T-cell engagers.
March 9th 2022
The pandemic appears to have caused or contributed to a number of lasting changes in the way oncologists provide clinical care to their patients.
February 17th 2022
The US Senate has confirmed Robert M. Califf, MD, a prominent cardiologist and expert in clinical trials, as the latest FDA commissioner today in a 50-46 vote.
February 10th 2022
The long-term dramatic effects of the COVID-19 pandemic on cancer research and patient care present several challenges but also future opportunities.
February 9th 2022
Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.
January 27th 2022
Patients with cancer should be fully immunized against COVID-19, including third doses and/or any approved boosters.
January 13th 2022
Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.
January 13th 2022
Christopher S. Lathan, MD, MS, MPH, discusses the lack of dissemination and implementation of evidence-based health care delivery innovations focused on addressing disparities in care.
January 5th 2022
The long-acting antibody combination of tixagevimab co-packaged with cilgavimab has been granted emergency use authorization in the United States for the pre-exposure prophylaxis of COVID-19.
December 25th 2021
A little self-reflection and a lot of self-compassion go a long way in a world of immense change.
December 24th 2021
At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.
December 12th 2021
Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.
December 1st 2021
Maurie Markman, MD, discusses how agency leaders should be encouraged to improve regulatory science, include a patient’s perspective in approval decisions, reduce unnecessary bureaucracy and costs associated with the conduct of trials, and accelerate the overall review process for drug approval.